A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants.
about
Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndromeAnimal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndromeProtein-containing synthetic surfactant versus protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndromeProtein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndromeProtein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndromeAn update on pharmacologic approaches to bronchopulmonary dysplasiaEfficient protein production inspired by how spiders make silkA systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials.Accounting for multiple births in neonatal and perinatal trials: systematic review and case study.Close mimicry of lung surfactant protein B by "clicked" dimers of helical, cationic peptoids.Comparison of poractant alfa and lyophilized lucinactant in a preterm lamb model of acute respiratory distress.Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.Synthetic lung surfactant reduces alveolar-capillary protein leakage in surfactant-deficient rabbits.The role of surfactant in respiratory distress syndromeNew synthetic surfactants: the next generation?Surfactant therapy in preterm infants with respiratory distress syndrome and in near-term or term newborns with acute RDS.A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa.New synthetic surfactant - how and when?Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases.European consensus guidelines on the management of neonatal respiratory distress syndrome.The helical structure of surfactant peptide KL4 when bound to POPC: POPG lipid vesicles.Surfactants: past, present and future.Interactions of the C-terminus of lung surfactant protein B with lipid bilayers are modulated by acyl chain saturation.Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: summary of clinical trialsPenetration depth of surfactant peptide KL4 into membranes is determined by fatty acid saturation.Delivery and performance of surfactant replacement therapies to treat pulmonary disorders.Surfactant respiratory therapy using Surfaxin/sinapultide.Synthetic surfactants: where are we? Evidence from randomized, controlled clinical trials.Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials.Lucinactant attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of RDSSurfactant in the preterm infant: what's going on.Lucinactant for the prevention of respiratory distress syndrome in premature infants.Adjunctive drug therapies for treatment of respiratory diseases in the newborn: based on evidence or habit?Infants at risk of cerebral palsy: a systematic review of outcomes used in Cochrane studies of pregnancy, childbirth and neonatology.A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome.Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future.Development of a Synthetic Surfactant Using a Surfactant Protein-C Peptide Analog: In Vitro Studies of Surface Physical Properties.Surfactant treatment before first breath for respiratory distress syndrome in preterm lambs: comparison of a peptide-containing synthetic lung surfactant with porcine-derived surfactant.Lucinactant: new and approved, but is it an improvement?Use of surfactants.
P2860
Q24187777-7363FA1C-41F3-475E-B945-ABDD769C1C7AQ24187839-5F533FB6-5D86-451B-B89A-513A15DB0F69Q24240106-C7D4AB91-0B6F-44E4-9701-2353FB67939EQ24243198-AAD9C107-546A-454B-8306-0C0256C54EA9Q24244224-3A18DE03-EAFE-4440-9317-30062A1CDB87Q26825139-C96D8DB0-DE8B-43CE-8954-4822C66D424BQ30854561-2323E96D-D05F-46C6-AAE4-48742EE8BC5EQ33517961-3E8B4B6B-5D64-487E-8546-A59EBEAA69A5Q33748656-C0C22A02-41D0-45A9-9E8F-E3F9DDB7DDDAQ33813691-77AD2E08-0636-445B-94BF-2B08D1A9A47BQ34215878-E1FF0DD9-BB7C-4064-A786-0BEED715AF65Q35086075-6B8185F1-FE49-4614-8618-D7E7BC67ECC0Q36113023-41B55C81-0A00-4830-83BD-DF52B32982F1Q36131235-F492548A-F06C-46D2-9CFE-8BF678EBEC18Q36178027-36A2B56F-B7DA-40C5-BB2E-30CD66D20579Q36453825-68D38344-5551-4156-A2BE-4EA0CC4E3979Q36479611-076F3CB5-BCD9-4042-8FF5-678A4775B15EQ36504555-80C75676-8359-4DD2-8BB8-8462C372871FQ36580296-DE1F3797-0BA6-4908-BCB3-2489DBC521E5Q36811513-2B613D0C-35C7-4CBD-A4CE-87F8C694458CQ37069359-E6499B94-1FE6-4212-899C-EA6484210B9FQ37150766-348827CF-03A9-42FC-9A2D-EE910A38B3F8Q37160113-6F44480C-77E8-479C-A756-B703C87739D2Q37230260-A309136F-F9C6-4548-B057-7FFBE50E22A2Q37265650-66B4E25F-90DA-43FE-8339-C79C60CA0AEAQ37341712-398A4A4E-15DF-48F3-B3CC-A98030B3C9A7Q37362645-AB47A815-DC60-409E-B038-5B1D113B352FQ37462109-1B25C427-324E-45F4-8A4F-AE4AAE84316BQ37462120-DBEFFDC0-E3CE-49CD-B4A0-CA20D66A5EA4Q37466166-CAAF03C0-4502-46AC-AD58-F7096691A0E8Q37635168-D610723E-621B-486D-9709-6F4EB4F2096BQ38087693-F7721585-CEAE-4ADB-8536-E340FA81DD0BQ38199558-D88C668B-BF05-4355-BA85-D09041696A55Q38256857-649BF18F-474B-4904-97FF-0FC8429C3108Q38808065-996E8566-264E-4F86-B26C-6884577F4CBFQ38814650-7AA81723-8EB8-41B4-8494-DC38DF85F392Q40246941-D7B6DF2F-D5B4-430C-A49E-89DA4AE43327Q42025793-3A0B0B80-C0B3-4698-86C3-DFF82ACB88A8Q42422372-075FD5FD-28A4-4AD5-85C8-C33595481881Q42535020-AE2253A1-9085-4289-A392-25F8D934593D
P2860
A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
A multicenter, randomized, mas ...... me among very preterm infants.
@en
A multicenter, randomized, mas ...... me among very preterm infants.
@nl
type
label
A multicenter, randomized, mas ...... me among very preterm infants.
@en
A multicenter, randomized, mas ...... me among very preterm infants.
@nl
prefLabel
A multicenter, randomized, mas ...... me among very preterm infants.
@en
A multicenter, randomized, mas ...... me among very preterm infants.
@nl
P2093
P356
P1433
P1476
A multicenter, randomized, mas ...... me among very preterm infants.
@en
P2093
Aldo Bancalari
Benjamin Kopelman
Christopher J Schaber
Eduardo Bancalari
Fernando R Moya
International Surfaxin Collaborative Study Group
Maria Katarzyna Kornacka
Ralph d'Agostino
Robert Segal
P304
P356
10.1542/PEDS.2004-2183
P407
P577
2005-04-01T00:00:00Z